ROIV Roivant Sciencesdata gap · 56% coveragelimited data
Health Care · Biotechnology · close $33.53 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Roivant Sciences (ROIV) has a ThetaGrade House Rating of 23/100 (grade F), ranking #65 of 150 in Health Care. Its strongest pillars are balance sheet (55) and growth (32); its weakest is valuation (0). Data gap: 6 factors without usable data, so 56% of the method weight is covered. TTM revenue growth is -67.6% and operating margin -7914.8%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), 4Q gross-margin change, Net debt / EBITDA, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 56% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 32| Revenue growth YoY (TTM) (22.2%) | -67.6% | 1 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | 33.2% | 94 |
Profitability
weight 18.5% (→20.0%) · 0| Operating margin (20.0%) | -7914.8% | 0 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 55| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (11.4%) | 16.72 | 93 |
| Interest coverage (8.6%) | -99.97× | 4 |
Cash flow
weight 12.33% (→13.3%) · 7| FCF margin (6.7%) | -9183.5% | 1 |
| FCF yield (6.7%) | -3.1% | 12 |
Valuation
weight 12.33% (→13.3%) · 0| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 3092.77× | 0 |
Technicals (EOD)
| RSI(14) | 37.5 |
| EMA 9 / 21 | 34.36 / 35.41 |
| 200-day SMA | 30.79 |
| Volume vs 20d avg | 0.69× |
| 20-day return | -16.1% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITFundamental miss: revenue growth negative YoY
- EXITBalance-sheet stress: negative free cash flow (latest FY)
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestPaidNet · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like ROIV's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is ROIV's House Rating?
- ROIV scores 23 out of 100 (grade F) as of 2026-10-16, ranking #65 of 150 Health Care stocks we cover.
- What do analysts say about ROIV?
- We do not have enough analyst-sentiment data to score this stock.
- When does ROIV report earnings next?
- We do not have a reliable estimate for ROIV's next earnings date (irregular SEC filing history); a rough window is 2026-11-01 to 2026-11-17. Check the company's investor-relations page.
- Is ROIV a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology